Catastrophic ape decline in western equatorial Africa

Additional co-authors: Yves Mihindou, Sosthène Ndong Obiang, Ernestine Ntsame Effa, Malcolm P. Starkey, Paul Telfer, Marc Thibault, Caroline E. G. Tutin, David S. Wilkie Output Type: Lette

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYC-FISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with 6 cycles of R2CHOP. At EOT, 67% (confidence interval (CI) 58-75%) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates (95% CI) for OS, DFS, EFS were 73% (62-82%), 75% (63-84%) and 63% (52-73%) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39).status: Published onlin

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide:results of a multicenter HOVON phase II trial

atients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in newly diagnosed MYC+ LBCL patients identified through a nationwide MYCFISH screening program. The primary endpoint was complete metabolic response (CMR) on centrally reviewed 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computer tomography (CT)-scan at end-of-treatment. Secondary endpoints were overall survival (OS), disease-free survival (DFS) and event-free survival (EFS). Eighty-two patients with stage II-IV MYC+ LBCL were treated with six cycles of R2CHOP. At end of treatment, 67% (95% Confidence interval [CI]: 58-75) of the patients reached CMR. With a median follow-up of 25.4 months, 2-year estimates for OS, DFS, EFS were 73% (95% CI: 62-82), 75% (95% CI: 63-84) and 63% change to: (95% CI: 52-73) respectively. In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yields comparable CMR and survival rates as in studies applying more intensive chemotherapy regimens. Hence, these findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized clinical trials. This trial was registered at www.clinicaltrialsregister.eu (#2014-002654-39)

Influence of tourism activities and PA size on threat level in 83 PAs.

<p>In bold are highlighted significant values (p <i><0.05</i>). See abbreviations in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114154#pone-0114154-t002" target="_blank">Tab 2</a>. AIC, Akaike's Information Criterion; AICw, Akaike Information Criterion weight; Rank, model rank from the smallest to the largest AIC value; k, number of variables including the intercept.</p><p>Influence of tourism activities and PA size on threat level in 83 PAs.</p

Proportion of protected areas with conservation activities between 1990 and 1999 across different African regions.

<p>The number of protected areas with available information on presence and absence of any conservation activity (research, tourism and law enforcement guards) over the considered period were in total 105.</p

Regional distribution of the protected areas (PAs) in tropical Africa considered in the analyses.

<p>The regions are coloured in different grey scale colours. Light grey represents West Africa, including 54 protected areas; medium grey represents Central Africa, including 31 protected areas; dark grey represents East Africa, including 14 protected areas. On the left-side bottom corner a MODIS NDVI image of Africa, with a red quadrant highlighting the tropical area considered in the study.</p